Apremilast was first marketed in March 2014 for the treatment of adults with psoriatic arthritis (PsA). An immunoÂmodulating drug, which is a small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monoÂphosphate (cAMP), apremilast is administered orally. By inhibiting PDE4, intracellular cAMP levels are increased. Although the exact mechanism of action is not…
